➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
AstraZeneca
Medtronic
McKesson
Boehringer Ingelheim

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PROCARBAZINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Procarbazine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002462 ↗ RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease Active, not recruiting European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1989-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with combination chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with no radiation therapy following chemotherapy in treating patients with stage III or stage IV Hodgkin's disease.
NCT00002463 ↗ Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed National Cancer Institute (NCI) Phase 2 1989-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine, vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive neuroectodermal tumors.
NCT00002463 ↗ Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed M.D. Anderson Cancer Center Phase 2 1989-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine, vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive neuroectodermal tumors.
NCT00002569 ↗ Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed Eastern Cooperative Oncology Group Phase 3 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
NCT00002569 ↗ Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed National Cancer Institute (NCI) Phase 3 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
NCT00002569 ↗ Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCIC Clinical Trials Group Phase 3 1994-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without chemotherapy in treating patients who have anaplastic oligodendroglioma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Procarbazine Hydrochloride

Condition Name

Condition Name for Procarbazine Hydrochloride
Intervention Trials
Lymphoma 32
Brain and Central Nervous System Tumors 17
Hodgkin Lymphoma 5
Neurotoxicity 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Procarbazine Hydrochloride
Intervention Trials
Lymphoma 46
Hodgkin Disease 37
Nervous System Neoplasms 20
Central Nervous System Neoplasms 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Procarbazine Hydrochloride

Trials by Country

Trials by Country for Procarbazine Hydrochloride
Location Trials
United States 369
Canada 25
United Kingdom 15
Germany 14
France 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Procarbazine Hydrochloride
Location Trials
New York 19
Ohio 18
Pennsylvania 15
Illinois 14
California 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Procarbazine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Procarbazine Hydrochloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 27
Phase 2/Phase 3 2
[disabled in preview] 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Procarbazine Hydrochloride
Clinical Trial Phase Trials
Completed 33
Active, not recruiting 13
Unknown status 13
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Procarbazine Hydrochloride

Sponsor Name

Sponsor Name for Procarbazine Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 25
European Organisation for Research and Treatment of Cancer - EORTC 9
University of Cologne 4
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Procarbazine Hydrochloride
Sponsor Trials
Other 129
NIH 26
Industry 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Colorcon
Harvard Business School
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.